Blood Test Could Predict Future Disability in MS
Measuring levels of neurofilament light chain in the blood could warn of worsening disability up to 2 years before it occurs.
Stay updated with breaking news from S Relapse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Measuring levels of neurofilament light chain in the blood could warn of worsening disability up to 2 years before it occurs.
COVID-19 has no impact on disease activity, progression, or cognitive performance in patients with multiple sclerosis.
Anti-CD20 antibody therapy can be effectively and safely administered subcutaneously to patients with MS, even when switching from a prior treatment, two clinical trials suggest.
A smartwatch and sophisticated artificial intelligence to analyze data could open a new frontier in monitoring disease progression, researchers say.
Measuring the thickness of the retina shortly after diagnosis in multiple sclerosis patients could predict their risk of accumulated disability later in the disease course, say Austrian researchers.